Evidence map›Paper›PMID 30992170›Full record

ArticleJournal of autoimmunity2019

Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.

Z Betteridge, S Tansley, G Shaddick, H Chinoy, R G Cooper, R P New, J B Lilleker, J Vencovsky, L Chazarain, K Danko and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of autoimmunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 4 pooled it
22.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 4 syntheses or guidelines pooled it, 284 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Emerging therapies in idiopathic inflammatory myopathies.Journal of neuromuscular diseases · 2026
    Review
  12. Article
  13. Article
  14. Autoantibodies as biomarkers of cancer risk in dermatomyositis.JID innovations : skin science from molecules to population health · 2026
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 4 countries.

Z BetteridgeDepartment of Pharmacy and Pharmacology, University of Bath, Bath, UK.
S TansleyDepartment of Pharmacy and Pharmacology, University of Bath, Bath, UK.
G ShaddickDepartment of Mathematics, University of Exeter, Exeter, UK.
H ChinoyCentre for Musculoskeletal Research, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; National Institute of Health Research Manchester Biomedical Research Centre, Manchester University Foundation Trust.UK; Salford Royal NHS Foundation Trust, Manchester, UK.
R G CooperInstitute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
R P NewInstitute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
J B LillekerCentre for Musculoskeletal Research, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; Salford Royal NHS Foundation Trust, Manchester, UK.
J VencovskyInstitute of Rheumatology and Department of Rheumatology, 1stMedical Faculty, Charles University, Prague, Czech Republic.
L ChazarainInstitute of Rheumatology and Department of Rheumatology, 1stMedical Faculty, Charles University, Prague, Czech Republic.
K DankoDepartment of Internal Medicine, University of Debrecen, Debrecen, Hungary.
M Nagy-VinczeDepartment of Internal Medicine, University of Debrecen, Debrecen, Hungary.
L BodokiDepartment of Internal Medicine, University of Debrecen, Debrecen, Hungary.
M DastmalchiDivision of Rheumatology, Department of Medicine, Solna Karolinska Institutet, And Karolinska University Hospital, Stockholm, Sweden.
L EkholmDivision of Rheumatology, Department of Medicine, Solna Karolinska Institutet, And Karolinska University Hospital, Stockholm, Sweden.
I E LundbergDivision of Rheumatology, Department of Medicine, Solna Karolinska Institutet, And Karolinska University Hospital, Stockholm, Sweden.
N McHughDepartment of Pharmacy and Pharmacology, University of Bath, Bath, UK. Electronic address: n.j.mchugh@bath.ac.uk.
UKMyonet contributors
University of Bath · GBUniversity of Debrecen · HUKarolinska University Hospital · SEUniversity of Liverpool · GBCharles University · CZInstitute of Rheumatology · CZKarolinska Institutet · SEManchester Academic Health Science Centre · GBSalford Royal NHS Foundation Trust · GBUniversity of Exeter · GB

Funding

Medical Research Council MR/N003322/1Versus Arthritis 18474
6 · The paper itself

Abstract

objectivesTo determine prevalence and co-existence of myositis specific autoantibodies (MSAs) and myositis associated autoantibodies (MAAs) and associated clinical characteristics in a large cohort of idiopathic inflammatory myopathy (IIM) patients.

methodsAdult patients with confirmed IIM recruited to the EuroMyositis registry (n = 1637) from four centres were investigated for the presence of MSAs/MAAs by radiolabelled-immunoprecipitation, with confirmation of anti-MDA5 and anti-NXP2 by ELISA. Clinical associations for each autoantibody were calculated for 1483 patients with a single or no known autoantibody by global linear regression modelling.

resultsMSAs/MAAs were found in 61.5% of patients, with 84.7% of autoantibody positive patients having a sole specificity, and only three cases (0.2%) having more than one MSA. The most frequently detected autoantibody was anti-Jo-1 (18.7%), with a further 21 specificities each found in 0.2-7.9% of patients. Autoantibodies to Mi-2, SAE, TIF1, NXP2, MDA5, PMScl and the non-Jo-1 tRNA-synthetases were strongly associated (p < 0.001) with cutaneous involvement. Anti-TIF1 and anti-Mi-2 positive patients had an increased risk of malignancy (OR 4.67 and 2.50 respectively), and anti-SRP patients had a greater likelihood of cardiac involvement (OR 4.15). Interstitial lung disease was strongly associated with the anti-tRNA synthetases, anti-MDA5, and anti-U1RNP/Sm. Overlap disease was strongly associated with anti-PMScl, anti-Ku, anti-U1RNP/Sm and anti-Ro60. Absence of MSA/MAA was negatively associated with extra-muscular manifestations.

conclusionsMyositis autoantibodies are present in the majority of patients with IIM and identify distinct clinical subsets. Furthermore, MSAs are nearly always mutually exclusive endorsing their credentials as valuable disease biomarkers.

Indexed as

AdultAgedAutoantibodiesCohort StudiesComorbidityDermatomyositisDisease SusceptibilityEuropeFemaleHumansMaleMiddle AgedMyositisOdds RatioPolymyositisPrevalenceAutoantibodiesAutoantibodiesAutoimmuneDermatomyositisMyositisPolymyositis

Identifiers

PMID30992170
PMCPMC6580360
OpenAlexW2938036544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.